Donald McDonnell, Professor in the Department of Pharmacology and Cancer Biology at Duke University School of Medicine, shared on LinkedIn:
“I am a translational researcher whose team focusses on the development of novel endocrine therapies for advanced breast and prostate cancer.
I am frequently asked ‘would it not be more efficient to leave drug discovery to colleagues in the private sector’.
I do not think that any of my answers to that question are as ‘on point’ as those made by Sally Kornbluth in this short interview.”
You can read more about breast oncology:
